Evidence map›Paper›PMID 38810608›Full record

GuidelineRespiration; international review of thoracic diseases2024

Treatment of MDR, Pre-XDR, XDR, and Rifampicin-Resistant Tuberculosis or in Case of Intolerance to at Least Rifampicin in Austria, Germany, and Switzerland.

Ralf Otto-Knapp, Torsten Bauer, Folke Brinkmann, Cornelia Feiterna-Sperling, Inna Friesen, Hilte Geerdes-Fenge, Pia Hartmann, Brit Häcker, Jan Heyckendorf, Martin Kuhns and 9 more

Abstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Respiration; international review of thoracic diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Ralf Otto-KnappDZK German Central Committee against Tuberculosis e.V., Berlin, Germany.
Torsten BauerDZK German Central Committee against Tuberculosis e.V., Berlin, Germany.
Folke BrinkmannDivision of Pneumology, Department of Pediatrics, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
Cornelia Feiterna-SperlingDepartment of Paediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Inna FriesenNational Reference Center for Mycobacteria, Research Center Borstel, Leibniz Lung Center, Borstel, Germany.
Hilte Geerdes-FengeDepartment of Pneumology, University of Rostock, Rostock, Germany.
Pia HartmannDepartment of Clinical Infectiology, St. Vinzenz-Hospital, Cologne, Germany.
Brit HäckerDZK German Central Committee against Tuberculosis e.V., Berlin, Germany.
Jan HeyckendorfDepartment of Internal Medicine I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Martin KuhnsNational Reference Center for Mycobacteria, Research Center Borstel, Leibniz Lung Center, Borstel, Germany.
Christoph LangeDepartment of Clinical Infectiology, Research Center Borstel, Borstel, Germany.
Florian P MaurerDepartment of Medical Microbiology, Virology and Hygiene, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.
Albert NienhausInstitute for Health Services Research in Dermatology and Nursing (IVDP), Universitätsklinikum Hamburg Eppendorf (UKE), Hamburg, Germany.
Martin PriwitzerPublic Health Department, Landeshauptstadt Stuttgart, Stuttgart, Germany.
Elvira RichterMVZ Labor Dr. Limbach and Colleagues GbR, Heidelberg, Germany.
Helmut J F SalzerDivision of Infectious Diseases and Tropical Medicine, Department of Internal Medicine 4 - Pneumology, Kepler University Hospital, Linz, Austria.
Otto D SchochKantonsspital St. Gallen, St. Gallen, Switzerland.
Nicolas SchönfeldLung Hospital Heckeshorn, Helios Klinikum Emil von Behring, Berlin, Germany.
Tom SchabergDZK German Central Committee against Tuberculosis e.V., Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Based on the assessment of new evidence, the World Health Organization (WHO) updated its guidelines for the treatment of drug-resistant tuberculosis (TB) in December 2022. The new recommendations and the latest study data made it necessary to update the existing guideline on the treatment of at least rifampicin-resistant TB (RR-TB) for the German-speaking countries, replacing the respective chapters of the treatment guidelines published in 2022. A shortened treatment of proven RR-TB and multidrug-resistant TB for at least 6 months using the fixed and non-modifiable drug combination of bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) is now also recommended for Austria, Germany, and Switzerland under certain conditions considering the existing barriers for the implementation of the new treatment regimen. For the treatment of pre-extensively drug-resistant (pre-XDR-) TB, an individualized treatment for 18 months continues to be the primary recommendation. The non-modifiable drug combination of bedaquiline, pretomanid, and linezolid (BPaL) may be used alternatively in selected pre-XDR-TB cases, provided that all prerequisites are met. The necessary requirements for using BPaLM and BPaL are presented in detail in this amendment to the consensus-based TB treatment guideline for adult patients.

Indexed as

Antitubercular AgentsExtensively Drug-Resistant TuberculosisRifampinTuberculosis, Multidrug-ResistantAustriaDiarylquinolinesGermanyHumansLinezolidMoxifloxacinSwitzerlandAntitubercular AgentsbedaquilineDiarylquinolinesLinezolidMoxifloxacinRifampinDrug availabilityDrug resistanceGuidelineMultidrug-resistant tuberculosisTuberculosis

Identifiers

PMID38810608
PMCPMC11373575

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.